To compare the short-term efficacy of intravitreal aflibercept and ranibizumab treatment according to the subtypes of polypoidal choroidal vasculopathy (PCV) based on indocyanine green angiography (ICGA). Methods: Fifty-five treatment naïve patients with PCV who underwent intravitreal anti-vascular endothelial growth factor (VEGF) (ranibizumab, 26 eyes; aflibercept, 29 eyes) injection were retrospectively analyzed. Based on ICGA, subjects with feeder and draining vessels were defined as type 1 PCV (33 eyes), and subjects who did not have either feeder or draining vessels, but had branch vascular networks were defined as type 2 PCV (22 eyes). The complete polyp regression was assessed at 3 months after the initial treatment using ICGA. Changes in best-corrected visual acuity (BCVA) and optical coherence tomographic parameters were evaluated at 3 and 6 months. Results: Patients with type 1 PCV showed a higher complete polyp regression percentage (p = 0.034) and better visual improvement (p = 0.017) after three monthly injections compared to patients with Type 2 PCV. At 3 and 6 months, the BCVA was significantly improved in type 1 PCV patients, but not in type 2 PCV patients. In patients with type 1 PCV, the aflibercept-treated group showed a better response in anatomical outcomes (p = 0.020), and complete polyp regression percentage (p = 0.027; dry macula) than the ranibizumab-treated group, and only the aflibercept-treated group showed a significant improvement of BCVA at 3 and 6 months. In patients with type 2 PCV, there were no significant differences in visual and anatomical outcome between the anti-VEGF agents. Conclusions: Type 1 PCV showed better visual improvement with a higher percentage of polyp regression than type 2 PCV. Anatomical changes were greater in patients treated with aflibercept than with ranibizumab, particularly in patients with type 1 PCV. These results suggest that a consideration of angiographic features is important in establishing a treatment strategy for patients with PCV.
. Comparison of the complete polyp regression between the aflibercept-and ranibizumab-treated groups. The aflibercept-treated group showed a better polyp regression than the ranibizumab-treated group in patients with type 1 polypoidal choroidal vasculopathy (PCV) (p = 0.020), while patients with type 2 PCV showed no significant difference between the two groups (p = 0.436). Patients with type 1 PCV showed a significantly higher regression percentage than patients with type 2 PCV in the aflibercept-treated group (p = 0.020), while the ranibizumab-treated group showed no significant difference between PCV types (p = 0.370). * p < 0.05, Fisher's exact test.
p=0.436, Type 2 PCV) ( Figure 3 . Outcomes of the 6-month treatment effects and comparisons between anti-vascular endothelial growth factor (anti-VEGF) agents. The aflibercept-treated group showed a better response than the ranibizumab-treated group (A, D, G, J). The anatomical changes were greater in patients treated with aflibercept than ranibizumab, particularly in patients with type 1 polypoidal choroidal vasculopathy (PCV) (B, E, H, K). In patients with type 2 PCV (C, F, I, L), there was no significant visual and anatomical difference between the anti-VEGF agents. BCVA = best-corrected visual acuity; PED = pigment epithelial detachment; CMT = central macular thickness; CT = choroidal thickness. * Parameters significantly changed from baseline (p < 0.05, Mann-Whitney U-test); † Changes in treatment effects that were significantly different between the anti-VEGF agents (p < 0.05, Mann-W hitney U test). 
